Press Room

JACKSON, Miss. – The Mississippi Senate passed Senate Bill 2694 Wednesday, February 11, paving the way for increased access to biomarker testing for patients across the Magnolia State.

Following today’s health-Medicaid budget hearing, more than a dozen cancer survivors and ACS CAN advocates gathered at the New York State Capitol to call on lawmakers to preserve access to biomarker testing, a priority shared by over 100 organizations statewide. Advocates also expressed hope that the one‑house and final budgets will include meaningful investments in cancer prevention and early detection. 

NASHVILLE, Tenn.

JACKSON, Miss. – Dozens of cancer patients, survivors, caregivers and advocates will come from across Mississippi to the State Capitol on Wednesday, February 4 for the American Cancer Society Cancer Action Network’s (ACS CAN) annual

JACKSON, Miss. –  The Mississippi House passed House Bill 565 Wednesday, paving the way for increased access to biomarker testing for patients across the Magnolia State.

With the 2026 legislative session now underway in Hawai’i, the American Cancer Society Cancer Action Network (ACS CAN) is leading efforts to work with lawmakers on several initiatives which include defending Medicaid and expanding access to screenings for colorectal cancer for the state’s most vu

Ahead of Mills' State of the State address, ACS CAN Calls Attention to Medicaid, Biomarker Testing and Medical Debt

 A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.

Massachusetts cancer survivors and caregivers urge lawmakers to support legislation that will increase access to precision medicine and patient navigation for all communities. 

Expanding access to this form of precision medicine will help more people in Connecticut get the right treatment at the right time.